| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Djillali Annane | Q30004548 |
| Marco Confalonieri | Q56381063 | ||
| P2093 | author name string | Didier Keh | |
| Eric Bellissant | |||
| Josef Briegel | |||
| Yizhak Kupfer | |||
| Pierre-Edouard Bollaert | |||
| Michael Oppert | |||
| G Umberto Meduri | |||
| Raffaele De Gaudio | |||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sepsis | Q183134 |
| systematic review | Q1504425 | ||
| septic shock | Q1765564 | ||
| P304 | page(s) | 2362-2375 | |
| P577 | publication date | 2009-06-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review | |
| P478 | volume | 301 |
| Q34321150 | 2013 WSES guidelines for management of intra-abdominal infections |
| Q64088330 | 2018 Year in Review in Critical Care |
| Q40243981 | A Randomized Controlled Trial of Corticosteroids in Pediatric Septic Shock: A Pilot Feasibility Study. |
| Q35034145 | A Single-Center Review of Prescribing Trends and Outcomes of Corticosteroid Replacement Therapy in Critically Ill Children with Septic Shock |
| Q40763138 | A new way of thinking: hydrocortisone in traumatic brain-injured patients |
| Q43440327 | A randomized controlled trial investigating the effects of parenteral fish oil on survival outcomes in critically ill patients with sepsis: a pilot study |
| Q26783984 | A systematic review and meta-analysis regarding the use of corticosteroids in septic arthritis |
| Q42751548 | Adjunct therapy for sepsis: how early? |
| Q40617446 | Adjunctive Corticosteroid Treatment Against Yersinia pestis Improves Bacterial Clearance, Immunopathology, and Survival in the Mouse Model of Bubonic Plague |
| Q26774000 | Adjunctive Corticotherapy for Community Acquired Pneumonia: A Systematic Review and Meta-Analysis |
| Q26862830 | Adrenal insufficiency in patients with decompensated cirrhosis |
| Q53710599 | Adrenocortical Stress Response during the Course of Critical Illness. |
| Q58742103 | Adrenocortical function during prolonged critical illness and beyond: a prospective observational study |
| Q35091711 | Advancing the science of organ donor management |
| Q84740729 | Adverse cardiac events during catecholamine therapy: a role for hydrocortisone? |
| Q42775761 | An ex vivo RT-qPCR-based assay for human peripheral leukocyte responsiveness to glucocorticoids in surgically induced inflammation. |
| Q92237890 | Are Corticosteroids Beneficial for Sepsis and Septic Shock? Based on Pooling Analysis of 16 Studies |
| Q83927887 | Arguments in favor of corticosteroids in pneumonia |
| Q98900256 | Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis |
| Q90695562 | Association of Corticosteroid Treatment With Outcomes in Adult Patients With Sepsis: A Systematic Review and Meta-analysis |
| Q42969992 | Biological and hemodynamic effects of low doses of fludrocortisone and hydrocortisone, alone or in combination, in healthy volunteers with hypoaldosteronism |
| Q36563509 | Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy. |
| Q41468819 | CAGS and ACS evidence based reviews in surgery. 35: Efficacy and safety of low-dose hydrocortisone therapy in the treatment of septic shock. |
| Q35558842 | CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis |
| Q40142223 | CRH Affects the Phenotypic Expression of Sepsis-Associated Virulence Factors by Streptococcus pneumoniae Serotype 1 In vitro |
| Q37805473 | Cardiogenic shock: the role of inflammation |
| Q38039884 | Cardiovascular management of septic shock in 2012. |
| Q42735019 | Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults |
| Q37924315 | Claims for improved survival from systemic corticosteroids in diverse conditions: an umbrella review |
| Q30396035 | Clinical aspects and cytokine response in severe H1N1 influenza A virus infection |
| Q35686356 | Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial. |
| Q30383661 | Clinical management of pandemic 2009 influenza A(H1N1) infection. |
| Q54567152 | Comparative effects of recombinant human activated protein C and dexamethasone in experimental septic shock. |
| Q38061038 | Contemporary perioperative care strategies. |
| Q50190740 | Continuous administration of corticosteroids in septic shock can reduce risk of hypernatremia |
| Q38291187 | Controversies surrounding critical illness-related corticosteroid insufficiency in animals |
| Q51151480 | Conventional and advanced time series estimation: application to the Australian and New Zealand Intensive Care Society (ANZICS) adult patient database, 1993–2006 |
| Q41760154 | Corticosteroid administration is associated with improved outcome of patients presenting high inflammatory cytokine levels during septic shock |
| Q36760001 | Corticosteroid therapy in refractory shock following cardiac arrest: a randomized, double-blind, placebo-controlled, trial. |
| Q33853198 | Corticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trial |
| Q30401605 | Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores |
| Q24186045 | Corticosteroids as adjunctive therapy in the treatment of influenza |
| Q24201063 | Corticosteroids as adjunctive therapy in the treatment of influenza |
| Q22918883 | Corticosteroids for dengue infection |
| Q24235735 | Corticosteroids for pneumonia |
| Q47317972 | Corticosteroids for pneumonia. |
| Q37781411 | Corticosteroids for sepsis: registry versus Cochrane systematic review! |
| Q39387531 | Corticosteroids for severe sepsis: an evidence-based guide for physicians |
| Q24187207 | Corticosteroids for treating sepsis |
| Q24247427 | Corticosteroids for treating severe sepsis and septic shock |
| Q90312235 | Corticosteroids in Acute Lung Injury: The Dilemma Continues |
| Q34462425 | Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis |
| Q33415746 | Corticosteroids in the treatment of dengue shock syndrome |
| Q39415929 | Corticotherapy for traumatic brain-injured patients--the Corti-TC trial: study protocol for a randomized controlled trial |
| Q39700586 | Cortisol is a potent modulator of lipopolysaccharide-induced interferon signaling in macrophages |
| Q34895613 | CryptoDex: a randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial |
| Q37702912 | Current concept of abdominal sepsis: WSES position paper. |
| Q30403288 | Cytokine response in pediatric patients with pandemic influenza H1N1 2009 virus infection and pneumonia: comparison with pediatric pneumonia without H1N1 2009 infection |
| Q34267818 | Delayed topical p38 MAPK inhibition attenuates full-thickness burn wound inflammatory signaling |
| Q40322885 | Dengue shock |
| Q40481255 | Detection of Serum Interleukin-6/10/18 Levels in Sepsis and Its Clinical Significance. |
| Q44077587 | Determinants of hospital mortality among patients with sepsis or septic shock receiving appropriate antibiotic treatment |
| Q42428132 | Dexmedetomidine Ameliorate CLP-Induced Rat Intestinal Injury via Inhibition of Inflammation |
| Q37924623 | Diagnosis of adrenal failure in critically ill patients. |
| Q38159505 | Diagnostics, therapy and outcome prediction in abdominal sepsis: current standards and future perspectives |
| Q39929445 | Differential effects of glucocorticoids in the establishment and maintenance of endotoxin tolerance |
| Q51701324 | Diurnal Variation of the Peripheral Cholinergic Antiinflammatory Function in Mice. |
| Q26745899 | Early goal-directed therapy in severe sepsis and septic shock: insights and comparisons to ProCESS, ProMISe, and ARISE |
| Q49259114 | Early immune anergy towards recall antigens and mitogens in patients at onset of septic shock |
| Q30368753 | Effect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis. |
| Q56553170 | Effect of early fluid resuscitation combined with low dose cyclophosphamide on intestinal barrier function in severe sepsis rats |
| Q33410125 | Effect of high dose of steroid on plateletcount in acute stage of dengue Fever with thrombocytopenia |
| Q35151568 | Effect of high-dose dexamethasone on perioperative lactate levels and glucose control: a randomized controlled trial |
| Q42650336 | Effects of inhaled carbon monoxide and glucocorticoids in porcine endotoxin sepsis. |
| Q35036775 | Effects of low-dose hydrocortisone therapy on immune function in neonatal horses |
| Q33402687 | Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial |
| Q36192686 | Efficacy and Safety of Adjunctive Corticosteroids Therapy for Severe Community-Acquired Pneumonia in Adults: An Updated Systematic Review and Meta-Analysis |
| Q40366933 | Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial |
| Q35624186 | Efficacy of selective mineralocorticoid and glucocorticoid agonists in canine septic shock |
| Q61757038 | Ergebnisse intensivmedizinischer Studien des Jahres 2009 |
| Q48294153 | Evidence-based critical care medicine: seeing through a glass darkly |
| Q40294910 | Fever control using external cooling in septic shock: a randomized controlled trial |
| Q21194917 | Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry |
| Q84128506 | Gluco- and mineralocorticoid biological effects of a 7-day treatment with low doses of hydrocortisone and fludrocortisone in septic shock |
| Q36975091 | Glucocorticoid receptor density and binding affinity in healthy horses and horses with systemic inflammatory response syndrome |
| Q84258052 | Glucocorticoid treatment in community-acquired pneumonia |
| Q98735430 | Glucocorticoids in Sepsis: To Be or Not to Be |
| Q37876499 | Glucocorticoids in sepsis: dissecting facts from fiction |
| Q41404165 | Glucocorticoids regulate the proliferation of T cells via miRNA-155 in septic shock |
| Q37398445 | Glucocorticosteroid in treatment of severe pneumonia |
| Q30655904 | Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis |
| Q36281234 | Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations |
| Q30399518 | H1N1 Influenza Pandemic of 2009 Compared With Other Influenza Pandemics: Epidemiology, Diagnosis, Management, Pulmonary Complications, and Outcomes. |
| Q30382674 | H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. |
| Q92619915 | Health economic evaluations of sepsis interventions in critically ill adult patients: a systematic review |
| Q57170719 | Hotspot Analysis of Sepsis Literature |
| Q37826436 | How I manage haematology patients with septic shock |
| Q55710423 | Hydrocortisone in septic shock: all the questions answered? |
| Q45931025 | Hydrocortisone increases the risk of dysglycemia in critically ill patients. |
| Q43115312 | Hydrocortisone therapy for patients with H1N1 influenza A infection. |
| Q90680354 | Impact and Beneficial Critical Points of Clinical Outcome in Corticosteroid Management of Adult Patients With Sepsis: Meta-Analysis and GRADE Assessment |
| Q37124621 | Impact and indication of early systemic corticosteroids for very severe community-acquired pneumonia. |
| Q51074798 | Improvement of side-effects and treatment on the experimental colitis in mice of a resin microcapsule-loading hydrocortisone sodium succinate. |
| Q41094806 | Incidence of pituitary dysfunction following traumatic brain injury: A prospective study from a regional neurosurgical centre. |
| Q35378402 | Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor alpha expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction. |
| Q44127294 | Is prolonged low-dose glucocorticoid treatment beneficial in community-acquired pneumonia? |
| Q36120203 | It's About Time …. |
| Q39054503 | Long-term changes in dysnatremia incidence in the ICU: a shift from hyponatremia to hypernatremia |
| Q41774754 | Low doses of fludrocortisone and hydrocortisone, alone or in combination, on vascular responsiveness to phenylephrine in healthy volunteers |
| Q41171549 | Low-dose corticosteroid treatment and mortality in refractory abdominal septic shock after emergency laparotomy |
| Q41730714 | Low-dose cyclophosphamide improves survival in a murine treatment model of sepsis |
| Q37829657 | Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies |
| Q41906922 | Macrophage migration inhibitory factor, infection, the brain, and corticosteroids |
| Q38207933 | Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). |
| Q37805910 | Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. |
| Q34175564 | Managing septic shock |
| Q36320106 | Methylprednisolone Protects Cardiac Pumping Mechanics from Deteriorating in Lipopolysaccharide-Treated Rats |
| Q42966817 | Methylprednisolone infusion for life-threatening H1N1-virus infection. |
| Q34185386 | New modalities in treating pneumococcal pneumonia |
| Q37443190 | One year mortality of patients treated with an emergency department based early goal directed therapy protocol for severe sepsis and septic shock: a before and after study |
| Q43097884 | Out-FOX(O)ing proteolysis in sepsis |
| Q30368680 | Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management |
| Q90427152 | Paclitaxel alleviated sepsis-induced acute lung injury by activating MUC1 and suppressing TLR-4/NF-κB pathway |
| Q38141738 | Pathophysiologic mechanisms in septic shock |
| Q35761448 | Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both? |
| Q47441844 | Plasma cytokine levels predict response to corticosteroids in septic shock |
| Q40979517 | Plesiomonas shigelloides Septic Shock Leading to Death of Postsplenectomy Patient with Pyruvate Kinase Deficiency and Hemochromatosis. |
| Q35245893 | Point accuracy and reliability of an interstitial continuous glucose-monitoring device in critically ill patients: a prospective study |
| Q41718237 | Postoperative immunosuppression markers and the occurrence of sepsis in patients with benign and malignant disease |
| Q90402431 | Protective effects of glucocorticoid on liver injury in a rat sepsis model |
| Q33879866 | Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH). |
| Q36986264 | RKIP contributes to IFN-γ synthesis by CD8+ T cells after serial TCR triggering in systemic inflammatory response syndrome |
| Q91692986 | Reevaluating the Role of Corticosteroids in Septic Shock: An Updated Meta-Analysis of Randomized Controlled Trials |
| Q58720877 | Refractory septic shock: our pragmatic approach |
| Q64964540 | Relative Adrenal Insufficiency in Pediatric Septic Shock. |
| Q42412734 | Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis |
| Q35230688 | Role of cytokines as a double-edged sword in sepsis |
| Q37664978 | Secondary immunodeficiencies, including HIV infection |
| Q26749485 | Sepsis and Acute Respiratory Distress Syndrome: Recent Update |
| Q59708886 | Sepsis and septic shock |
| Q89222248 | Sepsis and septic shock |
| Q38132155 | Sepsis: a review for the neurohospitalist |
| Q37655890 | Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding |
| Q26797235 | Septic Shock: Advances in Diagnosis and Treatment |
| Q33750076 | Septic serum induces glucocorticoid resistance and modifies the expression of glucocorticoid isoforms receptors: a prospective cohort study and in vitro experimental assay |
| Q44628126 | Severe scorpion envenomation among children: does hydrocortisone improve outcome? A case-control study. |
| Q37562996 | Severe sepsis and septic shock: management and performance improvement. |
| Q40657294 | Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study |
| Q54937509 | Steroids for sepsis: yes, no or maybe. |
| Q36664389 | Survival after shock requiring high-dose vasopressor therapy |
| Q38433744 | Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. |
| Q29615429 | Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 |
| Q22306309 | Systemic Steroids in Severe Sepsis and Septic Shock |
| Q35545874 | Terazosin activates Pgk1 and Hsp90 to promote stress resistance |
| Q84602457 | The "koala stress syndrome" and adrenal responsiveness in the critically ill |
| Q35906029 | The Effect of Adrenal Replacement Therapy on Rates of Fungal Colonization and Mortality in Critically Ill Patients Awaiting Liver Transplantation |
| Q87791624 | The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016) |
| Q50052469 | The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016). |
| Q35107094 | The Japanese guidelines for the management of sepsis |
| Q34483183 | The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill. |
| Q42676267 | The adrenocorticotropic hormone-induced cortisol response in acute pancreatitis |
| Q37849626 | The effect of etomidate on adrenal function in critical illness: a systematic review |
| Q58795848 | The glucocorticoid receptor and cortisol levels in pediatric septic shock |
| Q35155828 | The glucocorticoid receptor: a revisited target for toxins |
| Q38068423 | The immune response: targets for the treatment of severe sepsis |
| Q30386351 | The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness. |
| Q37676833 | The management of alcoholic hepatitis |
| Q36934401 | The pathogenesis of sepsis. |
| Q38064903 | The principles and conduct of anaesthesia for emergency surgery |
| Q27027974 | The role of complement system in septic shock |
| Q90074528 | The role of glucocorticoids as adjunctive treatment for sepsis in the modern era |
| Q48194718 | The role of steroids in treating septic shock |
| Q38949018 | Timing, method and discontinuation of hydrocortisone administration for septic shock patients |
| Q55069197 | Transforming growth factor-β-activated kinase 1 resistance limits glucocorticoid responsiveness to Toll-like receptor 4-mediated inflammation. |
| Q38009864 | Treatment with anti-inflammatory drugs in community-acquired pneumonia. |
| Q33919446 | Update on pediatric sepsis: a review. |
| Q34153235 | Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective. |
| Q30396672 | Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection |
| Q89280812 | [Corticoids in patients with septic shock : Adjunctive glucocorticoid therapy in patients with septic shock (ADRENAL) trial and Hydrocortisone plus fludrocortisone for adults with septic shock (APROCCHSS)] |
Search more.